Several antidepressants can cause breast enlargement in both men and women, with SSRIs carrying the highest risk among commonly prescribed options. In one study of 59 patients on chronic antidepressant therapy, 39% reported some degree of breast tissue growth, and SSRI users were significantly more likely to experience it than those taking other classes. The effect is tied to how these drugs interact with hormones that regulate breast tissue.
SSRIs Carry the Highest Risk
Among all antidepressant classes, SSRIs are most consistently linked to breast enlargement. Paroxetine (Paxil) stands out as the strongest offender. In clinical studies, paroxetine was the only SSRI to produce statistically significant increases in prolactin, the hormone responsible for breast tissue growth and milk production. It has also appeared in case reports of gynecomastia (male breast enlargement) specifically.
Other SSRIs associated with breast changes include fluoxetine (Prozac), sertraline (Zoloft), fluvoxamine (Luvox), and escitalopram (Lexapro). Fluoxetine has been reported to raise prolactin levels more than older tricyclic antidepressants, though individual responses vary considerably. Sertraline is notable because its effects appear to be dose-dependent. In one published case, a man developed breast tenderness and enlargement that worsened as his sertraline dose increased from 25 to 50 to 75 mg per day. When the drug was stopped, the symptoms resolved quickly.
How Antidepressants Cause Breast Growth
The connection runs through serotonin and a hormone called prolactin. Prolactin is the same hormone that triggers milk production during breastfeeding, but it also stimulates breast tissue growth in general. Your brain normally keeps prolactin in check through dopamine, which acts as a brake on prolactin release.
Antidepressants that boost serotonin activity can override that brake. Serotonin is a natural stimulator of prolactin release. It plays a role in the normal nighttime surges of prolactin and the prolactin spikes that occur during breastfeeding. When an SSRI floods the brain with extra serotonin, it can push prolactin levels higher than normal, a condition called hyperprolactinemia. That excess prolactin then acts on breast tissue, causing it to grow. This is why the effect isn’t limited to women: men have prolactin receptors in breast tissue too, and elevated levels can cause gynecomastia.
SNRIs, Tricyclics, and MAOIs
SNRIs like venlafaxine (Effexor) and duloxetine (Cymbalta) can also cause breast changes, but the risk is lower than with SSRIs. In the study comparing antidepressant classes, significantly fewer venlafaxine patients reported breast enlargement compared to SSRI users. That said, case reports of venlafaxine-induced gynecomastia do exist, and duloxetine has been flagged as well. The combination of multiple medications may increase risk. One case involved a patient who had taken sertraline and duloxetine separately without problems but developed gynecomastia when sertraline was added back alongside other drugs.
Among older antidepressants, clomipramine (a tricyclic) is the most clearly linked to prolactin elevation. Researchers confirmed the mechanism by showing that blocking serotonin receptors completely eliminated clomipramine’s effect on prolactin, proving the connection runs through the serotonin pathway. MAO inhibitors with serotonergic activity, including clorgiline and pargyline, have also been associated with breast-related side effects, though these drugs are rarely prescribed today.
Related Symptoms Beyond Enlargement
Breast enlargement from antidepressants often doesn’t happen in isolation. The same prolactin increase that drives tissue growth can trigger a cluster of related symptoms. Galactorrhea, the production of breast milk outside of pregnancy or nursing, is one of the more alarming possibilities. It typically shows up as a milky white discharge from both breasts. Antipsychotics and antidepressants are the medications most commonly associated with this symptom, according to the American Academy of Family Physicians.
Other signs of elevated prolactin include breast tenderness, menstrual irregularities (missed periods, lighter or heavier flow, irregular cycles), decreased sex drive, and in men, erectile dysfunction. If you’re experiencing breast changes alongside any of these, elevated prolactin from your antidepressant is a likely explanation. A simple blood test can confirm it.
What Happens if You’re Affected
The most effective approach is usually adjusting or switching the medication. Lowering the dose may be enough, since the effect can be dose-dependent. In the sertraline case mentioned earlier, symptoms worsened with each dose increase and resolved once the drug was stopped. Switching to an antidepressant with a different mechanism, such as bupropion (Wellbutid), which works on dopamine and norepinephrine rather than serotonin, can eliminate the prolactin issue entirely.
If changing the antidepressant isn’t practical because it’s working well for your mental health, medications that boost dopamine activity can sometimes counteract the prolactin elevation. These work by restoring the natural brake on prolactin that serotonin-heavy drugs disrupt. The breast changes are generally reversible once prolactin levels return to normal, though how quickly that happens varies from person to person.
Weight gain from antidepressants can also contribute to breast size changes independently of prolactin. Many SSRIs and SNRIs cause weight gain over time, and because breast tissue contains a significant amount of fat, general weight increase can add to the effect. Distinguishing between hormonal breast tissue growth and fat-related size change matters because the solutions differ.
Which Antidepressants Are Least Likely to Cause It
Bupropion (Wellbutrin) is the clearest low-risk option. It doesn’t significantly affect serotonin, so it doesn’t trigger the prolactin cascade that leads to breast changes. Mirtazapine (Remeron) works differently from SSRIs and is not commonly associated with prolactin elevation, though it does carry a higher risk of weight gain. Among SSRIs, the evidence suggests that sertraline and fluoxetine cause less prolactin elevation than paroxetine at standard doses, though individual variation is significant. Venlafaxine appears safer than SSRIs as a class for this specific side effect, even though isolated cases exist.